Is First Tracks Biotherapeutics Inc overvalued?

First Tracks Biotherapeutics Inc (TRAX) — key valuation metrics and fundamentals.

No verdict

Price

$44.04

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$1.54B

Dividend yield

0.0%

Return on equity

-30.1%

Sector

Healthcare

Fair value compares TRAX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.

Related stocks